Current trends in drug therapy for resectable locally advanced gastric cancer

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Gastric cancer is one of the most pressing problems in modern oncology. Surgery is currently the main treatment for resectable gastric cancer, but overall survival rates remain unsatisfactory. To date, combination therapy is the standard approach. Modern drug therapy, in addition to chemotherapy, includes targeted and immunotherapy, and it has changed significantly over the past few years. At the same time, perioperative chemotherapy regimens differ. In recent years, perioperative therapy using new agents such as targeted drugs and immune checkpoint inhibitors (ICIs) has also been investigated with promising results. Perioperative therapy has become an integral part of treatment strategies and requires further study. This review demonstrates modern perioperative therapy regimens, their recent achievements and presents future prospects.

Full Text

Restricted Access

About the authors

Konstantin S. Titov

S.P. Botkin Moscow Multidisciplinary Scientific and Clinical Center; People’s Friendship University of Russia (RUDN University)

Author for correspondence.
Email: ks-titov@mail.ru
ORCID iD: 0000-0003-4460-9136
SPIN-code: 7795-6512

Dr. Sci. (Med.), Professor, Leading Researcher, S.P. Botkin Moscow Multidisciplinary Scientific and Clinical Center; Professor, Department of Oncology and Roentgenology named after Academician V.P. Kharchenko, Medical Institute, People’s Friendship University of Russia (RUDN University)

Russian Federation, Moscow; Moscow

Igor L. Andreytsev

S.P. Botkin Moscow Multidisciplinary Scientific and Clinical Center

Email: ks-titov@mail.ru
ORCID iD: 0000-0002-6756-9555

Dr. Sci. (Med.), Leading Researcher

Russian Federation, Moscow

Dmitry N. Grekov

S.P. Botkin Moscow Multidisciplinary Scientific and Clinical Center; Russian Medical Academy of Continuous Professional Education

Email: ks-titov@mail.ru
ORCID iD: 0000-0001-8391-1210
SPIN-code: 6841-7128

Cand. Sci. (Med.), Associate Professor, Chief Physician, S.P. Botkin Moscow Multidisciplinary Scientific and Clinical Center; Associate Professor, Department of Surgery, Faculty of Surgery, Russian Medical Academy of Continuous Professional Education

Russian Federation, Moscow; Moscow

Aleksandr A. Kuzmenko

S.P. Botkin Moscow Multidisciplinary Scientific and Clinical Center

Email: ks-titov@mail.ru
ORCID iD: 0000-0002-1488-7795

Surgeon, Oncosurgical Department No. 72

Russian Federation, Moscow

Sergey S. Lebedev

S.P. Botkin Moscow Multidisciplinary Scientific and Clinical Center; Russian Medical Academy of Continuous Professional Education

Email: ks-titov@mail.ru
ORCID iD: 0000-0001-5366-1281

Dr. Sci. (Med.), Associate Professor, Deputy Chief Physician for Oncology, S.P. Botkin Moscow Multidisciplinary Scientific and Clinical Center; Professor, Department of Surgery, Faculty of Surgery, Russian Medical Academy of Continuous Professional Education

Russian Federation, Moscow; Moscow

Natalia M. Podzolkova

Russian Medical Academy of Continuous Professional Education

Email: ks-titov@mail.ru
ORCID iD: 0000-0001-9183-7030

Dr. Sci. (Med.), Professor, Head of the Department of Obstetrics and Gynecology

Russian Federation, Moscow

Antonio K. Chekini

S.P. Botkin Moscow Multidisciplinary Scientific and Clinical Center

Email: ks-titov@mail.ru
ORCID iD: 0000-0001-9065-4726
SPIN-code: 3114-0517

Cand.Sci. (Med.), Senior Researcher

Russian Federation, Moscow

Nikolay Yu. Sokolov

S.P. Botkin Moscow Multidisciplinary Scientific and Clinical Center

Email: ks-titov@mail.ru

Cand. Sci. (Med.), Head of the Oncology Department of Antitumor Drug Therapy No. 15

Russian Federation, Moscow

Alisa G. Minenkova

S.P. Botkin Moscow Multidisciplinary Scientific and Clinical Center

Email: ks-titov@mail.ru
ORCID iD: 0000-0001-6996-2724
Scopus Author ID: 57221414403

Physician, Resident in Surgery, Department of Surgery, Faculty of Surgery

Russian Federation, Moscow

References

  1. Sung H., Ferlay J., Siegel R.L., et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209–249. https://dx.doi.org/10.3322/caac.21660
  2. Bray F., Laversanne M., Sung H., et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2024 May-Jun;74(3):229–263. https://dx.doi.org/10.3322/caac.21834
  3. Camargo M.C., Anderson W.F., King J.B., et al. Divergent trends for gastric cancer incidence by anatomical subsite in US adults. Gut. 2011 Dec;60(12):1644–9. https://dx.doi.org/10.1136/gut.2010.236737
  4. Anderson W.F., Rabkin C.S., Turner N., et al. The Changing Face of Noncardia Gastric Cancer Incidence Among US Non-Hispanic Whites. J Natl Cancer Inst. 2018 Jun 1;110(6):608–615. https://dx.doi.org/10.1093/jnci/djx262
  5. Jun J.K., Choi K.S., Lee H.Y., et al. Effectiveness of the Korean National Cancer Screening Program in Reducing Gastric Cancer Mortality. Gastroenterology. 2017 May;152(6):1319–1328.e7. https://dx.doi.org/10.1053/j.gastro.2017.01.029
  6. Li Z., Shan F., Wang Y., et al. Correlation of pathological complete response with survival after neoadjuvant chemotherapy in gastric or gastroesophageal junction cancer treated with radical surgery: A meta-analysis. PLoS One. 2018 Jan 25;13(1):e0189294. https://dx.doi.org/10.1371/journal.pone.0189294
  7. Afanasyev S.G., Avgustinovich A.V., Davydov I.M., M. Yu. Volkov. Neoadjuvant chemotherapy in the combined treatment of gastric cancer. P A Herzen Journal of Oncology. 2014 Jan 1;3(6):13–3.
  8. Kim S.G., Seo H.S., Lee H.H., et al. Comparison of the Differences in Survival Rates between the 7th and 8th Editions of the AJCC TNM Staging System for Gastric Adenocarcinoma: a Single-Institution Study of 5,507 Patients in Korea. J Gastric Cancer. 2017 Sep;17(3):212–219. https://dx.doi.org/10.5230/jgc.2017.17.e23
  9. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Populations – Total U.S. 2022, National Cancer Institute, DCCPS, Surveillance Research Program.
  10. Sakuramoto S., Sasako M., Yamaguchi T., et al.; ACTS-GC Group. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007 Nov 1;357(18):1810–20. https://dx.doi.org/10.1056/NEJMoa072252 Erratum in: N Engl J Med. 2008 May 1;358(18):1977.
  11. Бесова Н.С., Болотина Л.В., Гамаюнов С.В. и др. Практические рекомендации по лекарственному лечению рака желудка. Практические рекомендации RUSSCO, часть 1. Злокачественные опухоли. 2023;13(#3s2):405–424.
  12. Ajani J.A., D’Amico T.A., Bentrem D.J., et al. Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022 Feb;20(2):167–192. https://dx.doi.org/10.6004/jnccn.2022.0008
  13. Lordick F., Carneiro F., Cascinu S., et al.; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022 Oct;33(10):1005–1020. https://dx.doi.org/10.1016/j.annonc.2022.07.004
  14. Kim T.H., Kim I.H., Kang S.J., et al. Korean Practice Guidelines for Gastric Cancer 2022: An Evidence-based, Multidisciplinary Approach (published correction appears in J Gastric Cancer. 2023 Apr;23(2):365-373. https://dx.doi.org/10.5230/jgc.2023.23.e20). J Gastric Cancer. 2023;23(1):3-106. https://dx.doi.org/10.5230/jgc.2023.23.e11
  15. Japanese Gastric Cancer Association. Japanese Gastric Cancer Treatment Guidelines 2021 (6th edition). Gastric Cancer. 2023 Jan;26(1):1–25. https://dx.doi.org/10.1007/s10120-022-01331-8
  16. Cunningham D., Allum W.H., Stenning S.P., et al., MAGIC Trial Participants. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006 Jul 6;355(1):11–20. https://dx.doi.org/10.1056/NEJMoa055531
  17. Al-Batran S.E., Homann N., Pauligk C., et al.; FLOT4-AIO Investigators. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet. 2019 May 11;393(10184):1948–1957. https://dx.doi.org/10.1016/S0140-6736(18)32557-1
  18. Kang Y.K., Yook J.H., Park Y.K., et al. PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer. J Clin Oncol. 2021 Sep 10;39(26):2903–2913. https://dx.doi.org/10.1200/JCO.20.02914
  19. Zhang X., Liang H., Li Z., et al.; RESOLVE study group. Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial. Lancet Oncol. 2021 Aug;22(8):1081–1092. https://dx.doi.org/10.1016/S1470-2045(21)00297-7 Epub 2021 Jul 9. Erratum in: Lancet Oncol. 2021 Aug;22(8):e347. https://dx.doi.org/10.1016/S1470-2045(21)00417-4
  20. Cunningham D., Allum W.H., Stenning S.P., et al., MAGIC Trial Participants. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006 Jul 6;355(1):11–20. doi: 10.1056/NEJMoa055531
  21. Petrelli F., Trevisan F., Cabiddu M., et al. Total Neoadjuvant Therapy in Rectal Cancer: A Systematic Review and Meta-analysis of Treatment Outcomes. Ann Surg. 2020 Mar;271(3):440–448. https://dx.doi.org/10.1097/SLA.0000000000003471
  22. Barrak D., Villano A.M., Villafane-Ferriol N., et al. Total neoadjuvant therapy for pancreatic adenocarcinoma increases probability for a complete pathologic response. Eur J Surg Oncol. 2022 Jan 5: S0748-7983(21)01445-1. https://dx.doi.org/10.1016/j.ejso.2021.12.473
  23. Murphy J.E., Wo J.Y., Ryan D.P., et al. Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial. JAMA Oncol. 2018 Jul 1;4(7):963–969. https://dx.doi.org/10.1001/jamaoncol.2018.0329
  24. Schulz C. et al. NeoFLOT: Multicenter phase II study of perioperative chemotherapy in resectable adenocarcinoma of the gastroesophageal junction or gastric adenocarcinoma-Very good response predominantly in patients with intestinal type tumors. Int J Cancer. 2015;137(3):678–685.
  25. Августинович А.В., Афанасьев С.Г., Добродеев А.Ю. и др. Непосредственная эффективность и токсичность тотальной неоадъювантной химиотерапии резектабельного рака желудка. Сибирский онкологический журнал. 2022;21(1):11-19. https://doi.org/10.21294/1814-4861-2022-21-1-11-19
  26. Yang J., Greally M., Strong V.E., et al. Perioperative versus total neoadjuvant chemotherapy in gastric cancer. J Gastrointest Oncol. 2023 Jun 30;14(3):1193–1203. https://dx.doi.org/10.21037/jgo-23-4
  27. Thuss-Patience P.C., Hofheinz R.D., Arnold D., et al. Perioperative chemotherapy with docetaxel, cisplatin and capecitabine (DCX) in gastro- oesophageal adenocarcinoma: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO) {dagger}. Ann Oncol 2012;23:2827-34. https://doi.org/10.1093/annonc/mds129
  28. Al-Batran S.-E. et al. Surgical and pathological outcome, and pathological regression, in patients receiving perioperative atezolizumab in combination with FLOT chemotherapy versus FLOT alone for resectable esophagogastric adenocarcinoma: Interim results from DANTE, a randomized, multicenter, phase IIb trial of the FLOT-AIO German Gastric Cancer Group and Swiss SAKK. J Clin Oncol. 2022;40(16_suppl.)4003–4003.
  29. Li Z., et al. «Evaluation of pathologic response and surgical safety of total neoadjuvant therapy for patients with clinical stage III gastric cancer in a real-world setting». Journal of gastrointestinal surgery: official journal of the Society for Surgery of the Alimentary Tract vol. 28,10 (2024): 1597-1604. https://doi.org/10.1016/j.gassur.2024.07.008
  30. Rencuzogullari A., Karahan S.N., Selcukbiricik F., et al. The New Era of Total Neoadjuvant FLOT Therapy for Locally Advanced, Resectable Gastric Cancer: A Propensity-Matched Comparison With Standard Perioperative Therapy. J Surg Oncol. 2024 Oct 13. https://doi.org/10.1002/jso.27934
  31. Ganschow P. et al. Operative Results and Perioperative Morbidity After Intensified Neoadjuvant Chemotherapy with FLOT for Gastroesophageal Adenocarcinoma Impact of Intensified Neoadjuvant Treatment. J Gastrointest Surg. 2021;25(1):58–66.
  32. Hofheinz R.D., Hegewisch-Becker S., Kunzmann V., et al. Trastuzumab in combination with 5-fluorouracil, leucovorin, oxaliplatin and docetaxel as perioperative treatment for patients with human epidermal growth factor receptor 2-positive locally advanced esophagogastric adenocarcinoma: A phase II trial of the Arbeitsgemeinschaft Internistische Onkologie Gastric Cancer Study Group. Int J Cancer. 2021 Sep 15;149(6):1322–1331. https://doi.org/10.1002/ijc.33696
  33. Hofheinz R.D. et al. Perioperative trastuzumab and pertuzumab in combination with FLOT versus FLOT alone for HER2-positive resectable esophagogastric adenocarcinoma: Final results of the PETRARCA multicenter randomized phase II trial of the AIO. Journal of Clinical Oncology. 2020;38(15_suppl.):4502–4502.
  34. Rivera F., Izquierdo-Manuel M., García-Alfonso P., et al. Perioperative trastuzumab, capecitabine and oxaliplatin in patients with HER2-positive resectable gastric or gastro-oesophageal junction adenocarcinoma: NEOHX phase II trial. Eur J Cancer. 2021 Mar;145:158–167. https://doi.org/10.1016/j.ejca.2020.12.005
  35. Cunningham D., Stenning S.P., Smyth E.C., et al. Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2–3 trial. Lancet Oncol. 2017 Mar;18(3):357–370. https://doi.org/10.1016/S1470-2045(17)30043-8
  36. Goetze T.O. et al. Perioperative ramucirumab in combination with FLOT versus FLOT alone for resectable esophagogastric adenocarcinoma (RAMSES/FLOT7) with high rate of signet cell component: Final results of the multicenter, randomized phase II/III trial of the German AIO and Italian GOIM. Journal of Clinical Oncology. 2022;40(16_suppl.):4042–4042.
  37. Al-Batran S.-E. et al. Surgical and pathological outcome, and pathological regression, in patients receiving perioperative atezolizumab in combination with FLOT chemotherapy versus FLOT alone for resectable esophagogastric adenocarcinoma: Interim results from DANTE, a randomized, multicenter, phase IIb trial of the FLOT-AIO German Gastric Cancer Group and Swiss SAKK. Journal of Clinical Oncology. 2022;40(16_suppl.):4003–4003.
  38. Li S. et al. A prospective, phase II, single-arm study of neoadjuvant/conversion therapy with camrelizumab, apatinib, S-1 ± oxaliplatin for locally advanced cT4a/bN+ gastric cancer. JCO. 2021;39:4061–4061. https://doi.org/10.1200/JCO.2021.39.15_suppl.4061
  39. Thierry Alcindor et al., Phase II trial of perioperative chemotherapy + avelumab in locally advanced gastroesophageal adenocarcinoma: Preliminary results. JCO. 2021;39:4046–4046. https://doi.org/10.1200/JCO.2021.39.15_suppl.4046
  40. Li H. et al., Phase II study of perioperative toripalimab in combination with FLOT in patients with locally advanced resectable gastric/gastroesophageal junction (GEJ) adenocarcinoma. JCO. 2021;39:4050–4050. https://doi.org/10.1200/JCO.2021.39.15_suppl.4050
  41. Yang Yang, Yi Li, Huiyao Gu, et al. Camrelizumab combined with FOLFOX as neoadjuvant therapy for resectable locally advanced gastric and gastroesophageal junction adenocarcinoma.. J Clin Oncol. 2020;38:4536–4536. https://doi.org/10.1200/JCO.2020.38.15_suppl.4536
  42. Masanori Terashima et al., ATTRACTION-5: A phase 3 study of nivolumab plus chemotherapy as postoperative adjuvant treatment for pathological stage III (pStage III) gastric or gastroesophageal junction (G/GEJ) cancer. JCO. 2023;41:4000–4000. https://doi.org/10.1200/JCO.2023.41.16_suppl.4000
  43. Bang Y..J., Van Cutsem E., Fuchs C.S., et al. KEYNOTE-585: Phase III study of perioperative chemotherapy with or without pembrolizumab for gastric cancer. Future Oncol. 2019 Mar;15(9):943–952. https://doi.org/10.2217/fon-2018-0581
  44. Yelena Y. Janjigian et al., MATTERHORN: Efficacy and safety of neoadjuvant-adjuvant durvalumab and FLOT chemotherapy in resectable gastric and gastroesophageal junction cancer – A randomized, double-blind, placebo-controlled, phase 3 study. JCO 39, TPS4151-TPS4151(2021). https://doi.org/10.1200/JCO.2021.39.15_suppl.TPS4151
  45. Thierry André et al., Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability–High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study. JCO. 2023;41:255–265. https://doi.org/10.1200/JCO.22.00686
  46. Pietrantonio F. et al. INFINITY: A multicentre, single-arm, multi-cohort, phase II trial of tremelimumab and durvalumab as neoadjuvant treatment of patients with microsatellite instability-high (MSI) resectable gastric or gastroesophageal junction adenocarcinoma (GAC/GEJAC). JCO. 2023;41:358–358. https://doi.org/10.1200/JCO.2023.41.4_suppl.358
  47. Leal A. et al. White blood cell and cell-free DNA analyses for detection of residual disease in gastric cancer. Nat Commun. 2020;11(1):525.
  48. Maron S.B., Chase L.M., Lomnicki S., et al. Circulating Tumor DNA Sequencing Analysis of Gastroesophageal Adenocarcinoma. Clin Cancer Res. 2019 Dec 1;25(23):7098–7112. https://doi.org/10.1158/1078-0432.CCR-19-1704
  49. Jin Y., Chen D.L., Wang F., et al. The predicting role of circulating tumor DNA landscape in gastric cancer patients treated with immune checkpoint inhibitors. Mol Cancer. 2020 Oct 30;19(1):154. https://doi.org/10.1186/s12943-020-01274-7

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2025 Bionika Media